Combination immunotherapy and chemotherapy for advanced acral or mucosal melanoma
Part of Cancer clinical trials.
This trial tests a combination of two immunotherapy drugs with standard chemotherapy (bevacizumab, albumin-bound paclitaxel, and carboplatin) for people with advanced acral or mucosal melanoma. The goal is to see if this combination can shrink tumors or slow the cancer's growth better than current treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 to 75 years old.
- Your melanoma must be the type that starts on the palms, soles, under nails, or in the moist linings of the body (like the mouth or nose).
- Your cancer has spread and cannot be removed with surgery, and you have had no more than one previous treatment for advanced disease.
- You need to be in reasonably good health to take part, with normal blood counts and kidney and liver function.
- If you are a woman who could become pregnant, you must agree to use birth control during the study and for 120 days after the last dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving two drugs (QL1706 and OH2) before and after surgery can help treat stage III acral melanoma, a type of skin cancer on the palms, soles, or under nails. The goal is to see if this approach reduces the chance of the cancer coming back.
This trial tests a combination of two drugs (carilizumab and apatinib) plus radiation therapy for people with advanced mucosal melanoma that has come back or spread. The goal is to see if this treatment can help control the cancer.
This Phase 3 trial tests camrelizumab (an immune-boosting medicine) combined with apatinib (a targeted pill) and temozolomide (chemotherapy) as first treatment for advanced acral melanoma. It may help shrink the cancer and improve outcomes compared with other standard first-line options.
This trial studies how well two medicines—axitinib and nivolumab—work for people with advanced melanoma that starts in moist “mucosal” areas (like the mouth, nose, throat, or bowel). It may help shrink tumors and control the disease by boosting the immune system and targeting tumor growth.
This trial tests two experimental drugs, AK104 or AK112, combined with a targeted therapy called axitinib for people with metastatic mucosal melanoma (a rare type of skin cancer that has spread). The goal is to see if these combinations can shrink tumors or slow the cancer's growth.
This trial tests whether a combination of two immunotherapy drugs (nivolumab and relatlimab) can clear tiny amounts of cancer cells that remain after surgery in people with high-risk melanoma. It aims to prevent the cancer from coming back.
Hear when a new Acral Melanoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.